# US 2019/0314379 A1 · Methods of using cannabinoid cb2 receptor agonist compositions to suppress and prevent opioid tolerance and withdrawal in a subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314379 A1
- Document ID: US20190314379A1
- Status: Published application
- Kind: A1
- Application number: 16/256,787
- Filed: 2019-01-24
- Published: 2019-10-17
- Earliest claimed: 2018-01-24
- Assignees: Indiana University Research and Technology Corporation
- Applicants: Indiana University Research and Technology Corporation
- Inventors: Andrea Grace HOHMANN; Ken Paul MACKIE; Xiaoyan LIN; Amey S. DHOPESHWARKAR
- Web page: https://patentgrep.com/patent/US20190314379A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of using cannabinoid CB2 receptor agonist compositions to suppress pain (e.g., neuropathic pain), opioid tolerance, and/or opioid-induced physical dependence in a subject.

## Claims

### Claim 1

A method of suppressing neuropathic pain without producing tolerance in a subject, the method comprising:
a) administering a pharmaceutical composition comprising a cannabinoid CB2 receptor agonist compound to the subject,
b) activating one or more G-protein signaling pathways that is sufficient to affect neuropathic pain in the subject,
c) improving one or more clinical manifestations of the neuropathic pain in the subject, and
d) suppressing the neuropathic pain in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human or a rodent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cannabinoid CB2 receptor agonist compound comprises a LY2828360 compound or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cannabinoid CB2 receptor agonist compound comprises an AM1710 compound or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof.

### Claim 5 (depends on 3)

The method of claim 3, wherein the LY2828360 compound comprises (8-(2-chlorophenyl)-2-methyl-6-(4-methylpiperazin-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine).

### Claim 6 (depends on 3)

The method of claim 3, wherein the LY2828360 compound has the following chemical structure:

### Claim 7 (depends on 4)

The method of claim 4, wherein the AM1710 compound comprises 3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c) chromen-6-one or has the following chemical structure:

### Claim 8 (depends on 3)

The method of claim 3, wherein activating the one or more G-protein signaling pathways by the LY2828360 compound occurs through a slow signaling mechanism.

### Claim 9 (depends on 4)

The method of claim 4, wherein activating of the one or more G-protein signaling pathways by the AM1710 compound occurs through a fast signaling mechanism.

### Claim 10

A method of reducing or preventing opioid withdrawal in a subject, the method comprising:
a) administering to the subject a pharmaceutical composition comprising a LY2828360 compound, an AM1710 compound, or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof,
b) activating one or more G-protein signaling pathways that affects opioid withdrawal in the subject,
c) suppressing the one or more clinical manifestations of the opioid withdrawal in the subject, and
d) reducing or preventing opioid withdrawal in the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the LY2828360 compound comprises (8-(2-chlorophenyl)-2-methyl-6-(4-methylpiperazin-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine).

### Claim 12 (depends on 10)

The method of claim 10, wherein the LY2828360 compound has the following chemical structure:

### Claim 13 (depends on 10)

The method of claim 10, wherein the AM1710 compound comprises 3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c) chromen-6-one or has the following chemical structure:

### Claim 14 (depends on 10)

The method of claim 10, wherein the one or more clinical manifestations of the opioid withdrawal comprises a plurality of withdrawal jumps.

### Claim 15 (depends on 10)

The method of claim 10, wherein the subject is a human or a rodent.

### Claim 16

A method of reducing or preventing the development of opioid tolerance in a subject, the method comprising:
a) co-administering to the subject one or more pharmaceutical compositions
comprising;
i) a LY2828360 compound, an AM1710 compound, or an analog, a derivative, a pharmaceutically acceptable salt, a hydrate, a prodrug, or a combination thereof, and
ii) an opioid;
b) activating one or more G-protein signaling pathways that effects opioid tolerance in the subject,
c) suppressing the development or presentation of one or more clinical manifestations of the opioid tolerance in the subject, and
d) reducing or preventing the development of opioid tolerance in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the subject is a human or a rodent.

### Claim 18 (depends on 16)

The method of claim 16, wherein the opioid is selected from the group consisting of morphine, codeine, oxycodone, oxycontin, hydrocodone, methadone, meperidine, buprenorphine, hydromorphone, tapentadol, tramadol, heroin, fentanyl, and their anlaogs.

### Claim 19 (depends on 16)

The method of claim 16, wherein the LY2828360 compound comprises (8-(2-chlorophenyl)-2-methyl-6-(4-methylpiperazin-1-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine) or the AM1710 compound comprises 3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c) chromen-6-one.

### Claim 20 (depends on 16)

The method of claim 16, wherein the LY2828360 compound has the following chemical structure:
or the AM1710 compound has the following chemical structure:
